NTX 303
Alternative Names: NTX-303Latest Information Update: 28 Aug 2023
At a glance
- Originator Southern Research
- Developer Pinotbio; Southern Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours in Australia (PO)
- 27 May 2021 Pinotbio in-licenses targeted anticancer agent from Southern Research (Pinotbio pipeline, May 2021)
- 13 May 2021 Pinotbio plans a phase I and phase II trials for Solid tumours (in combination with platinium-based anticancer drugs) in December 2023 in Australia (Pinotbio history, May 2021)